Phase 3 Nervous system disease Clinical Trials

6 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 16 of 6 trials

Recruiting
Phase 2Phase 3

Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke

Central Nervous System DiseasesCerebrovascular DisordersIschemic Stroke, Acute+1 more
University of Melbourne462 enrolled12 locationsNCT05892510
Recruiting
Phase 3

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Nervous system diseasePeripheral nervous system diseaseAmyloidosis+17 more
Intellia Therapeutics60 enrolled14 locationsNCT06672237
Recruiting
Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Phase 2Phase 3

Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms

Post Traumatic Stress DisorderMild Traumatic Brain InjuryAutonomic Nervous System Disease+2 more
Virginia Commonwealth University148 enrolled1 locationNCT07071350
Recruiting
Phase 3

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Demyelinating DiseasesMultiple SclerosisNervous System Diseases+3 more
Amsterdam UMC, location VUmc200 enrolled1 locationNCT05834855
Completed
Phase 3

A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.

Central nervous system diseases requiring a contrast-enhanced MRI of the CNS.
Bayer Australia Ltd402 enrolled7 locationsACTRN12608000455369